MCRB

Seres Therapeutics (MCRB)

About Seres Therapeutics (MCRB)

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Details

Daily high

$7.87

Daily low

$7.50

Price at open

$7.70

52 Week High

$29.98

52 Week Low

$6.53

Market cap

74.2M

Dividend yield

0.00%

Volume

27,911

Avg. volume

59,072

P/E ratio

-1.53

Seres Therapeutics News